Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

Margoni M, Preziosa P, Rocca MA, Filippi M

Open source

DOI
10.1007/s40263-026-01311-x
Published
2026 Aug
Container
CNS drugs
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s40263-026-01311-x,
  title = {Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.},
  author = {Margoni M and Preziosa P and Rocca MA and Filippi M},
  year = {2026},
  journal = {CNS drugs},
  doi = {10.1007/s40263-026-01311-x},
  url = {https://doi.org/10.1007/s40263-026-01311-x}
}

RIS

TY  - JOUR
TI  - Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.
AU  - Margoni M
AU  - Preziosa P
AU  - Rocca MA
AU  - Filippi M
PY  - 2026
JO  - CNS drugs
DO  - 10.1007/s40263-026-01311-x
UR  - https://doi.org/10.1007/s40263-026-01311-x
ER  - 

APA

M, M., P, P., MA, R., & M, F. (2026). Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.. CNS drugs. https://doi.org/10.1007/s40263-026-01311-x

Source records